MLchartDataset catalogue

alvocidib prodrug TP-1287

Term · Oncology and biomedicine · MLC-T-ONC-010013

An orally bioavailable, highly soluble phosphate prodrug of alvocidib, a potent inhibitor of cyclin-dependent kinase-9 (CDK9), with potential antineoplastic activity. Upon administration of the phosphate prodrug TP-1287, the prodrug is enzymatically cleaved at the tumor site and the active moiety alvocidib is released. Alvocidib targets and binds to CDK9, thereby reducing the expression of CDK9 target genes such as the anti-apoptotic protein MCL-1, and inducing G1 cell cycle arrest and apoptosis in CDK9-overexpressing cancer cells.

Table 1. Record
IdentifierMLC-T-ONC-010013
FieldOncology and biomedicine
Synonymsalvocidib phosphate TP-1287; alvocidib phosphate
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-010013",
  "term": "alvocidib prodrug TP-1287",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, highly soluble phosphate prodrug of alvocidib, a potent inhibitor of cyclin-dependent kinase-9 (CDK9), with potential antineoplastic activity. Upon administration of the phosphate prodrug TP-1287, the prodrug is enzymatically cleaved at the tumor site and the active moiety alvocidib is released. Alvocidib targets and binds to CDK9, thereby reducing the expression of CDK9 target genes such as the anti-apoptotic protein MCL-1, and inducing G1 cell cycle arrest and apoptosis in CDK9-overexpressing cancer cells.",
  "synonyms": [
    "alvocidib phosphate TP-1287",
    "alvocidib phosphate"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/alvocidib-prodrug-tp-1287/"
}

Record 933 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.